What were Bafna Pharmaceuticals Ltd's latest quarterly results?
Bafna Pharmaceuticals Ltd's latest quarterly results (Sep 2019) show
- PAT Growth YoY: +53.9% (insufficient data)
- Revenue Growth YoY: +30.9%
- Operating Margin: -3.3% (volatile)
Bafna Pharmaceuticals Ltd: Why Is It Outperforming Nifty 500?
ActiveRS +59.9%WeakNew This Week
In , Bafna Pharmaceuticals Ltd (Pharma - Formulators) is outperforming Nifty 500 with +59.9% relative strength. Fundamentals: Weak.
Bafna Pharmaceuticals Ltd Key Facts
- Market Cap
- ₹534 Cr
- PAT Growth YoY
- +54%
- Revenue Growth YoY
- +31%
- OPM
- -3.3%
- RS vs Nifty 500
- +59.9%
What's Happening
💪Debt reduced 93% YoY — balance sheet strengthening
👔Promoter stake down 13.3% this quarter
🌐FII stake increased 9.3% this quarter
Key Numbers
PAT Growth YoY
+54%
Insufficient Data
Revenue YoY
+31%
Insufficient Data
Operating Margin
-3.3%
-532 bps YoY
Current Price
₹226
Fundamental Score
32/100
Weak
3Y PAT CAGR
-16%
Market Cap
534 Cr
Valuation
N/A12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
How Fast Is Bafna Pharmaceuticals Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +31% | -14% | Insufficient Data |
| PAT (Net Profit) | +54% | -16% | Insufficient Data |
| OPM | -3.3% | -532 bps | Volatile |
Other Top Pharma - Formulators Stocks Beating Nifty 500
Frequently Asked Questions: Bafna Pharmaceuticals Ltd
Based on publicly available financial data. This is educational research, not investment advice.
Is Bafna Pharmaceuticals Ltd's profit growing or declining?
Bafna Pharmaceuticals Ltd's profit is growing with an insufficient data trend.
- PAT Growth YoY: +53.9% (latest quarter)
- PAT Growth QoQ: +72.3% (sequential)
- 3-Year PAT CAGR: -16.3%
- Trend: Insufficient data — consistent growth pattern
What is Bafna Pharmaceuticals Ltd's revenue growth trend?
Bafna Pharmaceuticals Ltd's revenue growth trend is insufficient data.
- Revenue Growth YoY: +30.9%
- Revenue Growth QoQ: +68.9% (sequential)
- 3-Year Revenue CAGR: -13.6%
How is Bafna Pharmaceuticals Ltd's operating margin trending?
Bafna Pharmaceuticals Ltd's operating margin is volatile.
- Current OPM: -3.3%
- OPM Change YoY: -5.3% basis points
- OPM Change QoQ: +38.5% basis points
What is Bafna Pharmaceuticals Ltd's 3-year profit and revenue CAGR?
Bafna Pharmaceuticals Ltd's long-term compounding rates
- 3-Year Profit CAGR: -16.3%
- 3-Year Revenue CAGR: -13.6%
Is Bafna Pharmaceuticals Ltd's growth accelerating or decelerating?
Bafna Pharmaceuticals Ltd's earnings growth is insufficient data with mixed signals on a sequential basis.
- YoY Acceleration: +14.4% bps
- Sequential Acceleration: +100.0% bps
- Margin Warning: Operating margins are under pressure
What is Bafna Pharmaceuticals Ltd's price-to-book ratio?
Bafna Pharmaceuticals Ltd's price-to-book ratio is 1.1x.
- Price-to-Book (P/B): 1.1x
- Book Value per Share: ₹216
- Current Price: ₹226
Is Bafna Pharmaceuticals Ltd a fundamentally strong company?
Bafna Pharmaceuticals Ltd is rated Weak with a fundamental score of 32/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +30.9% (10% weight)
- PAT Growth YoY: +53.9% (10% weight)
- PAT Growth QoQ: +72.3% (10% weight)
- Margins stable (10% weight)
Is Bafna Pharmaceuticals Ltd debt free?
Bafna Pharmaceuticals Ltd's debt position
- Total Debt: ₹3 Cr
What is Bafna Pharmaceuticals Ltd's return on equity (ROE) and ROCE?
Bafna Pharmaceuticals Ltd's return ratios over recent years
- FY2018: ROCE -36.0%
- FY2019: ROCE -22.0%
- FY2020: ROCE -3.0%
Is Bafna Pharmaceuticals Ltd's cash flow positive?
Bafna Pharmaceuticals Ltd's operating cash flow is negative (FY2020).
- Cash from Operations (CFO): ₹-34 Cr
- Free Cash Flow (FCF): ₹-1 Cr
What is Bafna Pharmaceuticals Ltd's dividend yield?
Bafna Pharmaceuticals Ltd currently does not pay a significant dividend (yield 0.00%).
- Dividend Yield: 0.00%
- Current Price: ₹226
Who holds Bafna Pharmaceuticals Ltd shares — promoters, FII, DII?
Bafna Pharmaceuticals Ltd's shareholding pattern (Mar 2026)
- Promoters: 75.0%
- FII (Foreign): 9.3%
- Public: 15.7%
Is promoter holding increasing or decreasing in Bafna Pharmaceuticals Ltd?
Bafna Pharmaceuticals Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 75.0% (Mar 2026)
- Previous Quarter: 75.0% (Dec 2025)
- Change: 0.00% (stable)
How long has Bafna Pharmaceuticals Ltd been outperforming Nifty 500?
Bafna Pharmaceuticals Ltd has been outperforming Nifty 500 for 1 consecutive week, indicating early-stage outperformance.
Is Bafna Pharmaceuticals Ltd a new momentum entry or an established outperformer?
Bafna Pharmaceuticals Ltd is a new entry this week — it just started outperforming Nifty 500. New entries are worth monitoring for follow-through.
Is Bafna Pharmaceuticals Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Bafna Pharmaceuticals Ltd may be worth studying
- Earnings growing at +53.9% YoY
What is the investment thesis for Bafna Pharmaceuticals Ltd?
Bafna Pharmaceuticals Ltd investment thesis summary:
Research Signals (Bull Case)
- Revenue growing at +30.9% YoY
Risk Factors (Bear Case)
- Margins under pressure
What is the future outlook for Bafna Pharmaceuticals Ltd?
Bafna Pharmaceuticals Ltd's forward outlook based on current data signals
- Earnings Trend: insufficient data
- Revenue Trend: insufficient data
- Margin Trend: volatile
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.